<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hemo-a" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hemo-a</book-part-id>
      <title-group>
        <title>Hemophilia A</title>
        <alt-title alt-title-type="alt-title">Synonym: Factor VIII Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Konkle</surname>
            <given-names>Barbara A</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="hemo-a.Tc.aff1"/>
          <email>barbarak@bloodworksnw.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huston</surname>
            <given-names>Haley</given-names>
          </name>
          <degrees>BS</degrees>
          <xref ref-type="aff" rid="hemo-a.Tc.aff2"/>
          <email>haleyh@bloodworksnw.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nakaya Fletcher</surname>
            <given-names>Shelley</given-names>
          </name>
          <degrees>BS</degrees>
          <xref ref-type="aff" rid="hemo-a.Tc.aff2"/>
          <email>shelleyn@bloodworksnw.org</email>
        </contrib>
      </contrib-group>
      <aff id="hemo-a.Tc.aff1">Associate Chief Scientific Officer<break/>Director, Hemostasis, Platelet Immunology and Genomics Laboratory <break/>Bloodworks Northwest <break/>Seattle, Washington</aff>
      <aff id="hemo-a.Tc.aff2">Genomics Laboratory<break/>Bloodworks Northwest<break/>Seattle, Washington</aff>
      <pub-history>
        <date date-type="created">
          <day>21</day>
          <month>9</month>
          <year>2000</year>
        </date>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>22</day>
          <month>6</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hlh" document-type="chapter">Hemophagocytic Lymphohistiocytosis, Familial</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hemo-b" document-type="chapter">Hemophilia B</related-object>
      <abstract id="hemo-a.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Hemophilia A is characterized by deficiency in factor VIII clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing. The age of diagnosis and frequency of bleeding episodes are related to the level of factor VIII clotting activity.</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with <italic toggle="yes">severe hemophilia A</italic> are usually diagnosed during the first two years of life following bleeding from minor mouth injuries and large "goose eggs" from minor head bumps. Without prophylactic treatment, they may average up to two to five spontaneous bleeding episodes each month including spontaneous joint bleeds or deep-muscle hematomas, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.</p>
            </list-item>
            <list-item>
              <p>Individuals with <italic toggle="yes">moderate hemophilia A</italic> seldom have spontaneous bleeding; however, they do have prolonged or delayed oozing after relatively minor trauma and are usually diagnosed before age five to six years; the frequency of bleeding episodes varies, usually from once a month to once a year.</p>
            </list-item>
            <list-item>
              <p>Individuals with <italic toggle="yes">mild hemophilia A</italic> do not have spontaneous bleeding episodes; however, without pre- and postoperative treatment, abnormal bleeding occurs with surgery or tooth extractions; the frequency of bleeding episodes varies widely, typically from once a year to once every ten years. Individuals with mild hemophilia A are often not diagnosed until later in life.</p>
            </list-item>
          </list>
          <p>Approximately 30% of heterozygous females have clotting activity below 40% and are at risk for bleeding (even if the affected family member is mildly affected). After major trauma or invasive procedures, prolonged or excessive bleeding usually occurs, regardless of severity.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of hemophilia A is established in an individual with low factor VIII clotting activity in the presence of a normal, functional von Willebrand factor level. Identification of a hemizygous <italic toggle="yes">F8</italic> pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis<italic toggle="yes">.</italic> Identification of a heterozygous <italic toggle="yes">F8</italic> pathogenic variant on molecular genetic testing in a symptomatic female confirms the diagnosis<italic toggle="yes">.</italic></p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Referral to a hemophilia treatment center (HTC) to facilitate treatment; intravenous infusion of factor VIII concentrate is most effective when infused within one hour of the onset of bleeding; training to facilitate home infusions administered by parents; immune tolerance therapy. For those with mild disease, including most symptomatic females, immediate treatment of bleeding with intravenous or nasal desmopressin acetate or factor VIII concentrate.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: For those with severe disease, prophylactic infusions of factor VIII concentrate three times a week or every other day to maintain factor VIII clotting activity higher than 1% nearly eliminates spontaneous bleeding and prevents chronic joint disease. Newer modified recombinant products with longer half-lives allow less frequent infusions.</p>
          <p><italic toggle="yes">Prevention of secondary complications.</italic> Reduction of bleeding and chronic joint disease is achieved by prophylactic treatment and prompt effective treatment of bleeding, including by use of home therapy.</p>
          <p><italic toggle="yes">Surveillance</italic>: For individuals with severe or moderate hemophilia A, assessments including inhibitor screen every six to 12 months at an HTC are recommended; for individuals with mild hemophilia A, assessment at an HTC every one to two years. Comorbidities may require more frequent visits.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Circumcision of at-risk males until hemophilia A is either excluded or treated with factor VIII concentrate regardless of severity; intramuscular injections; activities with a high risk of trauma, particularly head injury; cautious, if any, use of medications and herbal remedies that affect platelet function, including aspirin.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: To clarify genetic status of females at risk before pregnancy or early in pregnancy and to facilitate management.</p>
          <p><italic toggle="yes">Pregnancy management</italic>: Monitor heterozygous females during pregnancy and for delayed bleeding post partum unless it is known that their baseline factor VIII clotting activity is normal.</p>
          <p><italic toggle="yes">Therapies under investigation</italic>: Ongoing clinical trials of longer-acting factor VIII concentrates, bypassing agents, and gene therapy.</p>
          <p><italic toggle="yes">Other</italic>: Vitamin K does not prevent or control bleeding in hemophilia A; cryoprecipitate contains factor VIII but does not undergo viral inactivation so is no longer used to treat hemophilia A.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Hemophilia A is inherited in an X-linked manner. The risk to sibs of a proband depends on the carrier status of the mother. Carrier females have a 50% chance of transmitting the <italic toggle="yes">F8</italic> pathogenic variant in each pregnancy: sons who inherit the pathogenic variant will be affected; daughters who inherit the pathogenic variant are carriers. Affected males transmit the pathogenic variant to all of their daughters and none of their sons. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">F8</italic> pathogenic variant has been identified or if informative intragenic linked markers have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hemo-a.Diagnosis">
        <title>Diagnosis</title>
        <sec id="hemo-a.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Hemophilia A <bold>should be suspected</bold> in an individual with any of the following clinical and/or laboratory features.</p>
          <p>
            <bold>Clinical features</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Hemarthrosis, especially with mild or no antecedent trauma</p>
            </list-item>
            <list-item>
              <p>Deep-muscle hematomas</p>
            </list-item>
            <list-item>
              <p>Intracranial bleeding in the absence of major trauma</p>
            </list-item>
            <list-item>
              <p>Neonatal cephalohematoma or intracranial bleeding</p>
            </list-item>
            <list-item>
              <p>Prolonged oozing or renewed bleeding after initial bleeding stops following tooth extractions, mouth injury, or circumcision&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Prolonged or delayed bleeding or poor wound healing following surgery or trauma&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Unexplained GI bleeding or hematuria&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Menorrhagia, especially with onset at menarche</p>
            </list-item>
            <list-item>
              <p>Prolonged nosebleeds, especially recurrent and bilateral&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Excessive bruising, especially with firm, subcutaneous hematomas</p>
            </list-item>
          </list>
          <p>*&#x000a0;Of any severity, or especially in more severely affected persons</p>
          <p>
            <bold>Laboratory features</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Normal platelet count</p>
            </list-item>
            <list-item>
              <p>Prolonged activated partial thromboplastin time (aPTT)</p>
            </list-item>
            <list-item>
              <p>Normal prothrombin time (PT)</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemo-a.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p><bold>Male proband.</bold> The diagnosis of hemophilia A <bold>is established</bold> in a male proband by identification of deceased factor VIII clotting activity and a normal, functional von Willebrand factor level.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Severe hemophilia A.</bold> &#x0003c;1% factor VIII</p>
            </list-item>
            <list-item>
              <p><bold>Moderate hemophilia A.</bold> 1%-5% factor VIII</p>
            </list-item>
            <list-item>
              <p><bold>Mild hemophilia A.</bold> 6%-40% factor VIII</p>
            </list-item>
          </list>
          <p>Note: Rarely, in individuals with mild hemophilia A, a standard "one-stage" factor VIII clotting activity assay shows near-normal or low-normal factor VIII clotting activity (40%-80%), whereas in a "two-stage" or chromogenic assay, factor VIII activity is low. Thus, low-normal in vitro clotting activity does not always exclude the presence of mild hemophilia A.</p>
          <p>Identification of a hemizygous pathogenic variant in <italic toggle="yes">F8</italic> by molecular genetic testing can help predict the clinical phenotype, assess the risk of developing a factor VIII inhibitor, and allow family studies (see <xref ref-type="table" rid="hemo-a.T.molecular_genetic_testing_used">Table 1</xref>).</p>
          <p><bold>Female proband.</bold> The diagnosis of hemophilia A <bold>is established</bold> by determination of low factor VIII clotting activity. Carrier status is determined by identification of a heterozygous pathogenic variant in <italic toggle="yes">F8</italic> by molecular genetic testing (see <xref ref-type="table" rid="hemo-a.T.molecular_genetic_testing_used">Table 1</xref>). Factor VIII clotting activity is unreliable in the detection of heterozygous females; only approximately 30% of hemophilia A heterozygous females have factor VIII clotting activity lower than 40% [<xref ref-type="bibr" rid="hemo-a.REF.plug.2006.52">Plug et al 2006</xref>].</p>
          <sec id="hemo-a.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Single-gene testing.</bold> Targeted analysis for the intron 22 or intron 1 inversion is frequently performed first in (a) individuals with severe hemophilia A, (b) females with a family history of severe hemophilia A, or (c) females with a family history of hemophilia A of unknown severity in whom the family-specific pathogenic variant is not known.</p>
                <p>Sequence analysis of <italic toggle="yes">F8</italic> followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found is performed if the common intron 22 or intron 1 inversion is not detected.</p>
              </list-item>
              <list-item>
                <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">F8</italic> and other genes of interest (see <xref ref-type="sec" rid="hemo-a.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests. (4) The ability of panels to detect structural variants in <italic toggle="yes">F8</italic>, a common cause of hemophilia A, should be confirmed.</p>
                <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
              </list-item>
              <list-item>
                <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes <italic toggle="yes">F8</italic>) fails to confirm a diagnosis in an individual with features of hemophilia A. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).</p>
                <p>For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
              </list-item>
            </list>
            <table-wrap id="hemo-a.T.molecular_genetic_testing_used" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in Hemophilia A</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_2">Test Method</th>
                    <th id="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                  <tr>
                    <th headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Severe Hemophilia A</th>
                    <th headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Moderate or Mild Hemophilia A</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">F8</italic>
                    </td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted mutation analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3 hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~48%&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3 hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">0%&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>5,&#x000a0;6</sup></td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3 hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~43%-51%&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3 hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">76%-99%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3 hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">1.5%&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_1_3 hd_h_hemo-a.T.molecular_genetic_testing_used_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">0.2%&#x000a0;<sup>9</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="hemo-a.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="hemo-a" object-id="hemo-a.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="hemo-a.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="hemo-a.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="hemo-a.TF.1.3">
                  <label>3. </label>
                  <p>Intron 22 and intron 1 inversions can be detected by multiple techniques (e.g., long-range PCR [<xref ref-type="bibr" rid="hemo-a.REF.bagnall.2006.591">Bagnall et al 2006</xref>], inverse PCR [<xref ref-type="bibr" rid="hemo-a.REF.rossetti.2008.830">Rossetti et al 2008</xref>]), PCR-based &#x0201c;inverse shifting&#x0201d; procedure [<xref ref-type="bibr" rid="hemo-a.REF.radic.2009.1183">Radic et al 2009</xref>]). Intron 22 inversions can be accompanied by adjacent deletions or duplications.</p>
                </fn>
                <fn id="hemo-a.TF.1.4">
                  <label>4. </label>
                  <p>An intron 22 inversion is identified in approximately 43%-45% of individuals with severe hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.kaufman.2013">Kaufman et al 2013</xref>, <xref ref-type="bibr" rid="hemo-a.REF.johnsen.2017.824">Johnsen et al 2017</xref>]. An intron 1 inversion is identified in 2%-5% of individuals with severe hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.gouw.2012.2922">Gouw et al 2012</xref>, <xref ref-type="bibr" rid="hemo-a.REF.johnsen.2017.824">Johnsen et al 2017</xref>] and has not been described in families with moderate or mild hemophilia A.</p>
                </fn>
                <fn id="hemo-a.TF.1.5">
                  <label>5. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="hemo-a.TF.1.6">
                  <label>6. </label>
                  <p>Lack of amplification by PCR prior to sequence analysis or loss of coverage in next-generation sequencing can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.</p>
                </fn>
                <fn id="hemo-a.TF.1.7">
                  <label>7. </label>
                  <p><xref ref-type="bibr" rid="hemo-a.REF.kemballcook.1998.216">Kemball-Cook et al [1998]</xref>, <xref ref-type="bibr" rid="hemo-a.REF.elmaarri.2005.332">El-Maarri et al [2005]</xref>, <xref ref-type="bibr" rid="hemo-a.REF.kaufman.2013">Kaufman et al [2013]</xref>, <xref ref-type="bibr" rid="hemo-a.REF.johnsen.2017.824">Johnsen et al [2017]</xref></p>
                </fn>
                <fn id="hemo-a.TF.1.8">
                  <label>8. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="hemo-a.TF.1.9">
                  <label>9. </label>
                  <p>Deletions and duplications detected using MLPA in 2353 males with severe hemophilia A or 1709 males with moderate/mild hemophilia A in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.mylifeourfuture.org/">MyLifeOurFuture</ext-link> project [<xref ref-type="bibr" rid="hemo-a.REF.johnsen.2017.824">Johnsen et al 2017</xref>]</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v19/n11/full/ejhg2011107a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="hemo-a.REF.keeney.2011">Keeney et al 2011</xref>] for information on test characteristics including sensitivity and specificity.</p>
          </sec>
        </sec>
      </sec>
      <sec id="hemo-a.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hemo-a.Clinical_Description">
          <title>Clinical Description</title>
          <p>Hemophilia A in the untreated individual is characterized by immediate or delayed bleeding or prolonged oozing after injuries, tooth extractions, or surgery or renewed bleeding after initial bleeding has stopped [<xref ref-type="bibr" rid="hemo-a.REF.fogarty.2013">Fogarty &#x00026; Kessler 2013</xref>, <xref ref-type="bibr" rid="hemo-a.REF.josephson.2013">Josephson 2013</xref>]. Muscle hematomas or intracranial bleeding can occur four or five days after the original injury. Intermittent oozing may last for days or weeks after tooth extraction. Prolonged or delayed bleeding or wound hematoma formation after surgery is common. After circumcision, males with hemophilia A of any severity may have prolonged oozing, or they may heal normally without treatment. In severe hemophilia A, spontaneous joint bleeding is the most frequent symptom.</p>
          <p>The age of diagnosis and frequency of bleeding episodes in the untreated individual are related to the factor VIII clotting activity (see <xref ref-type="table" rid="hemo-a.T.symptoms_related_to_severity_of">Table 2</xref>). In any affected individual, bleeding episodes may be more frequent in childhood and adolescence than in adulthood. To some extent, this greater frequency is a function of both physical activity levels and vulnerability during more rapid growth.</p>
          <p><bold>Individuals with severe hemophilia A</bold> are usually diagnosed in the neonatal period due to birth- or neonatal-related procedures or during the first year of life [<xref ref-type="bibr" rid="hemo-a.REF.kulkarni.2009.1281">Kulkarni et al 2009</xref>]. In untreated toddlers, bleeding from minor mouth injuries and large "goose eggs" from minor head bumps are common and are the most frequent presenting symptoms of severe hemophilia A. Intracranial bleeding may also result from head injuries. The untreated child almost always has subcutaneous hematomas; some have been referred for evaluation of possible non-accidental trauma.</p>
          <p>As the child grows and becomes more active, spontaneous joint bleeds occur with increasing frequency unless the child is on a prophylactic treatment program. Spontaneous joint bleeds or deep-muscle hematomas initially cause pain or limping before swelling appears. Children and adults with severe hemophilia A who are not treated prophylactically have an average of two to five spontaneous bleeding episodes each month. While joints are the most common sites of spontaneous bleeding, other sites include the kidneys, gastrointestinal tract, and brain. Without prophylactic treatment, individuals with severe hemophilia A have prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions.</p>
          <p><bold>Individuals with moderate hemophilia A</bold> seldom have spontaneous bleeding but bleeding episodes may be precipitated by relatively minor trauma. Without pretreatment (as for elective invasive procedures) they do have prolonged or delayed oozing after relatively minor trauma and are usually diagnosed before age five to six years. The frequency of bleeding episodes requiring treatment with factor VIII concentrates varies from once a month to once a year. Signs and symptoms of bleeding are otherwise similar to those found in severe hemophilia A.</p>
          <p><bold>Individuals with mild hemophilia A</bold> do not have spontaneous bleeding. However, without treatment abnormal bleeding occurs with surgery, tooth extractions, and major injuries. The frequency of bleeding may vary from once a year to once every ten years. Individuals with mild hemophilia A are often not diagnosed until later in life when they undergo surgery or tooth extraction or experience major trauma.</p>
          <p><bold>Heterozygous females</bold> with a factor VIII clotting activity level lower than 40% are at risk for bleeding that is usually comparable to that seen in males with mild hemophilia. However, subtle abnormal bleeding may occur with a baseline factor VIII clotting activity between 35% and 60% or higher [<xref ref-type="bibr" rid="hemo-a.REF.plug.2006.52">Plug et al 2006</xref>, <xref ref-type="bibr" rid="hemo-a.REF.paroskie.2015.223">Paroskie et al 2015</xref>].</p>
          <table-wrap id="hemo-a.T.symptoms_related_to_severity_of" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Symptoms Related to Severity of Untreated Hemophilia A</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Severity</th>
                  <th id="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Factor VIII Clotting Activity&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Symptoms</th>
                  <th id="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Usual Age at Diagnosis</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Severe</bold>
                  </td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Frequent spontaneous bleeding; abnormal bleeding after minor injuries, surgery, or tooth extractions</td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Age &#x02264;2 years&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Moderate</bold>
                  </td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1%-5%</td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Rare spontaneous bleeding; abnormal bleeding after minor injuries, surgery, or tooth extractions</td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Age &#x0003c;5-6 years</td>
                </tr>
                <tr>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Mild</bold>
                  </td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;5%-40%</td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">No spontaneous bleeding; abnormal bleeding after major injuries, surgery, or tooth extractions</td>
                  <td headers="hd_h_hemo-a.T.symptoms_related_to_severity_of_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Often later in life, depending on hemostatic challenges</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hemo-a.TF.2.1">
                <label>1. </label>
                <p>Clinical severity does not always correlate with the in vitro assay result.</p>
              </fn>
              <fn id="hemo-a.TF.2.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="hemo-a.REF.kulkarni.2009.1281">Kulkarni et al [2009]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Complications of untreated bleeding.</bold> The leading cause of death related to bleeding is intracranial hemorrhage. The major cause of disability from bleeding is chronic joint disease [<xref ref-type="bibr" rid="hemo-a.REF.luck.2004.234">Luck et al 2004</xref>]. Currently available treatment with clotting factor concentrates is normalizing life expectancy and reducing chronic joint disease for children and adults with hemophilia A. Prior to the availability of such treatment, the median life expectancy for individuals with severe hemophilia A was 11 years (the current life expectancy for affected individuals in several developing countries). Excluding death from HIV, life expectancy for severely affected individuals in the UK receiving adequate treatment was reported in 2007 as 63 years [<xref ref-type="bibr" rid="hemo-a.REF.darby.2007.815">Darby et al 2007</xref>].</p>
          <p><bold>Other.</bold> Since the mid-1960s, the mainstay of treatment of bleeding episodes has been factor VIII concentrates that initially were derived solely from donor plasma. Viral inactivation methods and donor screening of plasmas were introduced by the mid-1980s and recombinant factor VIII concentrates were introduced in the early 1990s, ending the risk of HIV transmission. Many individuals who received plasma-derived factor VIII concentrates from 1979 to 1985 contracted HIV. Approximately half of these individuals died of AIDS prior to the advent of effective HIV therapy.</p>
          <p>Hepatitis B transmission from earlier plasma-derived concentrates was eliminated with donor screening and then vaccination in the 1970s. Most individuals exposed to plasma-derived concentrates prior to the late 1980s became chronic carriers of the hepatitis C virus. Viral inactivation methods implemented in concentrate preparation and donor screening assays developed by 1990 have eliminated this complication.</p>
          <p>Approximately 30% of individuals with severe hemophilia A develop alloimmune inhibitors to factor VIII, usually within the first 20 exposures to infused factor VIII [<xref ref-type="bibr" rid="hemo-a.REF.hay.2011.6367">Hay et al 2011</xref>] and, less frequently, in those who have received more than 50 exposures [<xref ref-type="bibr" rid="hemo-a.REF.kempton.2010.61">Kempton 2010</xref>, <xref ref-type="bibr" rid="hemo-a.REF.eckhardt.2013.1954">Eckhardt et al 2013</xref>] (see <bold>Management,</bold>
<xref ref-type="sec" rid="hemo-a.Treatment_of_Manifestations">Treatment of Manifestations</xref>). Among individuals with hemophilia A, inhibitors are more prevalent in blacks and Hispanics than whites. Reasons for these disparities are being actively investigated [<xref ref-type="bibr" rid="hemo-a.REF.viel.2009.1618">Viel et al 2009</xref>, <xref ref-type="bibr" rid="hemo-a.REF.miller.2012.375">Miller et al 2012</xref>, <xref ref-type="bibr" rid="hemo-a.REF.schwarz.2013.113">Schwarz et al 2013</xref>].</p>
        </sec>
        <sec id="hemo-a.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>
            <bold>Evidence for an association between variant type and disease severity</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">F8</italic> intron 22 inversions are associated with severe hemophilia A and account for 45% of individuals with severe hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.kaufman.2013">Kaufman et al 2013</xref>]. Of these, 20% to 30% develop alloimmune inhibitors. Occasionally, individuals considered to have moderate hemophilia A have been found to have <italic toggle="yes">F8</italic> inversions. Often their assays have contained either some residual factor VIII clotting activity from a prior transfusion or the assay methods used were inaccurate at low levels.</p>
            </list-item>
            <list-item>
              <p>An inversion between a 1-kb sequence in intron 1 and an inverted repeat 5' to <italic toggle="yes">F8</italic> [<xref ref-type="bibr" rid="hemo-a.REF.bagnall.2002.168">Bagnall et al 2002</xref>] is also associated with a severe phenotype, and some individuals have developed inhibitors.</p>
            </list-item>
            <list-item>
              <p>Single-nucleotide variants leading to new stop codons are essentially all associated with a severe phenotype, as are most frameshift variants. (An exception is the insertion or deletion of adenosine bases resulting in a sequence of eight to ten adenosines, which may result in moderate hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.nakaya.2001.977">Nakaya et al 2001</xref>].)</p>
            </list-item>
            <list-item>
              <p>Splice site variants often result in severe disease, but can result in mild or moderate disease, depending on the specific change and location.</p>
            </list-item>
            <list-item>
              <p>Missense variants occur in fewer than 20% of individuals with severe hemophilia A but are found in nearly all of those with a diagnosis of mild or moderate disease.</p>
            </list-item>
            <list-item>
              <p>A single-base change in the 5&#x02019; promoter region of <italic toggle="yes">F8</italic> has been associated with mild hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.riccardi.2009.1234">Riccardi et al 2009</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemo-a.Penetrance">
          <title>Penetrance</title>
          <p>All males with an <italic toggle="yes">F8</italic> pathogenic variant will be affected and will have approximately the same severity of disease as other affected males in the family. However, other genetic and environmental effects may modify the clinical severity to some extent.</p>
          <p>Approximately 30% of females with one <italic toggle="yes">F8</italic> pathogenic variant and one normal allele have a factor VIII clotting activity lower than 40% and a bleeding disorder; mild bleeding can occur in heterozygous females with low-normal factor VIII activity [<xref ref-type="bibr" rid="hemo-a.REF.plug.2006.52">Plug et al 2006</xref>]. Overall, carriers have more bleeding than unaffected females [<xref ref-type="bibr" rid="hemo-a.REF.paroskie.2015.223">Paroskie et al 2015</xref>].</p>
        </sec>
        <sec id="hemo-a.Nomenclature">
          <title>Nomenclature</title>
          <p>Hemophilia A has also been referred to as &#x0201c;classic hemophilia.&#x0201d;</p>
        </sec>
        <sec id="hemo-a.Prevalence">
          <title>Prevalence</title>
          <p>The birth prevalence of hemophilia A in the United States is approximately 1:6,500 live male births. Worldwide the birth prevalence for hemophilia A and B has been estimated at 1:10,000, although reports vary widely between countries [<xref ref-type="bibr" rid="hemo-a.REF.stonebraker.2010.20">Stonebraker et al 2010</xref>, <xref ref-type="bibr" rid="hemo-a.REF.srivastava.2013">Srivastava et al 2013</xref>].</p>
          <p>The birth prevalence is thought to be approximately the same in all countries and all races, presumably because of the high spontaneous mutation rate of <italic toggle="yes">F8</italic> and its presence on the X chromosome.</p>
        </sec>
      </sec>
      <sec id="hemo-a.Genetically_Related_Allelic_Disor">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are associated with pathogenic variants in <italic toggle="yes">F8.</italic></p>
      </sec>
      <sec id="hemo-a.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Increased bleeding with trauma, tonsillectomy, or for a few hours following tooth extraction may be seen in individuals without a bleeding disorder. In contrast, prolonged or intermittent oozing that lasts several days following tooth extraction or mouth injury, renewed bleeding or increased pain and swelling several days after an injury, or developing a wound hematoma several days after surgery almost always indicates a coagulation problem. A detailed history of bleeding episodes can help determine if the individual has a lifelong, inherited bleeding disorder or an acquired (often transient) bleeding disorder. An older individual with severe or moderate hemophilia A may have joint deformities and muscle contractures. Large bruises and subcutaneous hematomas for which no trauma can be identified may be present, but individuals with a mild bleeding disorder have no outward signs except during an acute bleeding episode. Petechial hemorrhages indicate severe thrombocytopenia and are not a feature of hemophilia A.</p>
        <sec id="hemo-a.Inherited_Bleeding_Disorders_with">
          <title>Inherited Bleeding Disorders with a Low Factor VIII Clotting Activity</title>
          <p><bold>Type 1</bold>
<related-object link-type="booklink" source-id="gene" document-id="von-willebrand" document-type="chapter"><bold>von Willebrand disease</bold></related-object>
<bold>(VWD)</bold> is characterized by a partial quantitative deficiency of von Willebrand factor (low VWF antigen, low factor VIII clotting activity, and low VWF activity). Mucous membrane bleeding and prolonged oozing after surgery or tooth extractions are the predominant symptoms. VWF levels can differentiate mild hemophilia A from VWD. Individuals with hemophilia A have a normal VWF antigen level. Inheritance is autosomal dominant; penetrance varies.</p>
          <p><bold>Type 2A and 2B VWD</bold> are characterized by a qualitative deficiency of VWF with a decrease of the high molecular-weight multimers. Measures of VWF platelet or collagen binding activity are decreased, while VWF antigen and factor VIII clotting activity may be low-normal to mildly decreased. Type 2A VWD is caused by pathogenic variants resulting in abnormal multimer formation or stability. Type 2B VWD is caused by a gain of function in platelet binding and is often accompanied by thrombocytopenia. Molecular genetic testing can aid in diagnosis. Type 2A and 2B VWD are typically inherited in an autosomal dominant manner.</p>
          <p><bold>Type 2M VWD</bold> is also characterized by a qualitative deficiency of VWF with a similar decrease in function as seen in type 2A; however, it is associated with a normal multimer pattern. Molecular genetic testing can aid in the diagnosis. Inheritance is autosomal dominant.</p>
          <p><bold>Type 2N VWD</bold> is an uncommon variant resulting from one of several missense variants in the amino terminus of the circulating VWF protein, resulting in defective binding of factor VIII to VWF. VWF platelet binding is completely normal. Clinically and biochemically, type 2N VWD is indistinguishable from mild hemophilia A; however, mild hemophilia A can be distinguished from type 2N VWD by molecular genetic testing of <italic toggle="yes">F8</italic>, molecular genetic testing of <italic toggle="yes">VWF</italic>, or measuring binding of factor VIII to VWF using ELISA or column chromatography. Inheritance is autosomal recessive.</p>
          <p><bold>Type 3 VWD</bold> is characterized by a complete or near-complete quantitative deficiency of VWF. Affected individuals experience frequent episodes of mucous membrane bleeding and joint and muscle bleeding similar to that seen in individuals with hemophilia A. The VWF level is often lower than 1% and the factor VIII clotting activity is most commonly 2%-8%. Inheritance is autosomal recessive. Heterozygous parents may have type 1 VWD but more often are asymptomatic.</p>
          <p><bold>Mild combined factor V and factor VIII deficiencies</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613625">613625</ext-link>) are usually caused by rare autosomal recessive inheritance of a deficiency of one of two intracellular chaperone proteins encoded by <italic toggle="yes">LMAN1</italic> or <italic toggle="yes">MCFD2</italic> [<xref ref-type="bibr" rid="hemo-a.REF.zhang.2008.5592">Zhang et al 2008</xref>].</p>
        </sec>
        <sec id="hemo-a.Bleeding_Disorders_with_a_Normal">
          <title>Bleeding Disorders with a Normal Factor VIII Clotting Activity</title>
          <p><related-object link-type="booklink" source-id="gene" document-id="hemo-b" document-type="chapter"><bold>Hemophilia B</bold></related-object><bold>,</bold> caused by mutation of <italic toggle="yes">F9</italic>, is clinically indistinguishable from hemophilia A. Diagnosis is based on a factor IX clotting activity lower than 40%. Inheritance is X-linked.</p>
          <p><bold>Factor XI deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612416">612416</ext-link>) is caused by mutation of <italic toggle="yes">F11</italic>. Heterozygotes have a factor XI coagulant activity of 25% to 75% of normal while homozygotes have activity of lower than 1% to 15% [<xref ref-type="bibr" rid="hemo-a.REF.duga.2013.621">Duga &#x00026; Salomon 2013</xref>]. Two pathogenic variants are common among individuals of Ashkenazi Jewish descent. Both compound heterozygotes and homozygotes may exhibit bleeding similar to that seen in mild or moderate hemophilia A. A specific factor XI clotting assay establishes the diagnosis.</p>
          <p><bold>Factor XII</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/234000">234000</ext-link>), <bold>prekallikrein</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612423">612423</ext-link>), or <bold>high molecular-weight kininogen deficiencies</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/228960">228960</ext-link>) do not cause clinical bleeding but can cause a long activated partial thromboplastin time (aPTT).</p>
          <p><bold>Prothrombin (factor II)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613679">613679</ext-link>), <bold>factor V</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/227400">227400</ext-link>), <bold>factor X</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/227600">227600</ext-link>), and <bold>factor VII</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/227500">227500</ext-link>) <bold>deficiencies</bold> are rare bleeding disorders inherited in an autosomal recessive manner. Individuals may display easy bruising and hematoma formation, epistaxis, menorrhagia, and bleeding after trauma and surgery. Hemarthroses are uncommon. Spontaneous intracranial bleeding can occur. Factor VII deficiency should be suspected if the PT is prolonged and aPTT normal. Individuals with deficiency of factors II, V, or X usually have prolonged PT and aPTT, but specific coagulation factor assays establish the diagnosis. Combined (multiple) deficiencies are usually acquired disorders, although a few families have hereditary deficits of the vitamin K-dependent factors, often resulting from deficiency of gamma-carboxylase.</p>
          <p><bold>Inherited fibrinogen disorders</bold> include complete (afibrinogenemia) or partial (hypofibrinogenemia) fibrinogen deficiency. <bold>Afibrinogenemia</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/202400">202400</ext-link>) is a rare disorder inherited in an autosomal recessive manner with manifestations similar to hemophilia A except that bleeding from minor cuts is prolonged because of the lack of fibrinogen to support platelet aggregation. <bold>Hypofibrinogenemia</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616004">616004</ext-link>) can be inherited in either an autosomal dominant or an autosomal recessive manner. In <bold>dysfibrinogenemia</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616004">616004</ext-link>) there is discordance between the functional and antigenic level, with the latter usually in the normal range. Dysfibrinogenemia is inherited in an autosomal dominant manner. Individuals with hypofibrinogenemia or dysfibrinogenemia have mild-to-moderate bleeding symptoms or may be asymptomatic; rarely individuals with dysfibrinogenemia are at risk for thrombosis. For all fibrinogen disorders the thrombin and reptilase times are almost always prolonged and functional measurements of fibrinogen decreased.</p>
          <p><bold>Factor XIII deficiency</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613225">613225</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613235">613235</ext-link>) is a rare autosomal recessive disorder. Umbilical stump bleeding occurs in more than 80% of individuals. Intracranial bleeding that occurs spontaneously or following minor trauma is seen in 30% of individuals. Subcutaneous hematomas, muscle hematomas, defective wound healing, and recurrent spontaneous abortion are also seen. Joint bleeding is rare. All coagulation screening tests are normal; a screening test for clot solubility or a specific assay for factor XIII (FXIII) activity can confirm the diagnosis.</p>
          <p><bold>Platelet function disorders</bold> include Bernard-Soulier syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231200">231200</ext-link>), Glanzmann thrombasthenia (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/273800">273800</ext-link>), and storage pool and nonspecific secretory defects. Individuals with platelet function disorders have skin and mucous membrane bleeding, recurring epistaxis, gastrointestinal bleeding, menorrhagia, and excessive bleeding during or immediately after trauma and surgery. Joint, muscle, and intracranial bleeding is rare. Diagnosis is made using platelet aggregation assays, flow cytometry, and platelet electron microscopy.</p>
        </sec>
      </sec>
      <sec id="hemo-a.Management">
        <title>Management</title>
        <sec id="hemo-a.Evaluations_Following_Initial_Dia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with hemophilia A, the following evaluations are recommended if they have not already been completed:</p>
          <list list-type="bullet">
            <list-item>
              <p>A personal and family history of bleeding to help predict disease severity</p>
            </list-item>
            <list-item>
              <p>A joint and muscle evaluation, particularly if the individual describes a history of hemarthrosis or deep-muscle hematomas</p>
            </list-item>
            <list-item>
              <p>Screening for hepatitis A, B, and C as well as HIV if blood products or plasma-derived clotting factor concentrates were administered prior to 1990</p>
            </list-item>
            <list-item>
              <p>Baseline CBC with a platelet count, especially if there is a history of nose bleeds, GI bleeding, mouth bleeding, or (in females) menorrhagia or postpartum hemorrhage</p>
            </list-item>
            <list-item>
              <p>Referral to a hemophilia treatment center. For locations:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Worldwide, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.wfh.org/en/page.aspx?pid=1264">World Federation of H&#x000e6;mophilia</ext-link>;</p>
                </list-item>
                <list-item>
                  <p>US only, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hemophilia.org/">National Hemophilia Foundation</ext-link>.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Identification of the specific <italic toggle="yes">F8</italic> pathogenic variant in an individual to aid in determining disease severity, the likelihood of inhibitor development, and the chance that immune tolerance will be successful if an inhibitor does develop</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor, particularly for a new diagnosis in the family and for females of childbearing years</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemo-a.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The World Federation of Hemophilia has published <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www1.wfh.org/publications/files/pdf-1472.pdf">treatment guidelines</ext-link> for the management of individuals with hemophilia. Treatment should be coordinated through a hemophilia treatment center. (Individuals in the USA see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hemophilia.org/">National Hemophilia Foundation</ext-link>; individuals worldwide see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.wfh.org/en/page.aspx?pid=1264">World Federation of Hemophilia</ext-link> for locations).</p>
          <p><bold>Intravenous infusion of plasma-derived or recombinant factor VIII</bold> for bleeding episodes within an hour of noticing symptoms:</p>
          <list list-type="bullet">
            <list-item>
              <p>Dosing is weight based and target levels and duration of treatment vary by the severity of bleeding and/or the risk associated with the surgery or procedure.</p>
            </list-item>
            <list-item>
              <p>Staff members who are expert in performing venipunctures in infants and toddlers should be identified, as frequent venipunctures may be necessary.</p>
            </list-item>
            <list-item>
              <p>Parents of children age two to five years with severe hemophilia A should be trained to administer the infusions. Home treatment allows for prompt treatment and facilitates prophylactic therapy.</p>
            </list-item>
          </list>
          <p><bold>Pediatric issues.</bold> Special considerations for care of infants and children with hemophilia A include the following [<xref ref-type="bibr" rid="hemo-a.REF.chalmers.2011.208">Chalmers et al 2011</xref>, <xref ref-type="bibr" rid="hemo-a.REF.srivastava.2013">Srivastava et al 2013</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Infant males with a family history of hemophilia A should not be circumcised unless hemophilia A is either excluded or, if present, is treated with factor VIII concentrate directly before and after the procedure.</p>
            </list-item>
            <list-item>
              <p>Immunizations should be administered preferably subcutaneously; intramuscular injections should be avoided unless under factor coverage.</p>
            </list-item>
            <list-item>
              <p>Effective dosing of factor VIII requires an understanding of different pharmacokinetics in young children.</p>
            </list-item>
          </list>
          <p><bold>DDAVP</bold><sup>&#x000ae;</sup>
<bold>(desmopressin acetate).</bold> For individuals with mild hemophilia A, including symptomatic females, immediate treatment of bleeding can be achieved with DDAVP<sup>&#x000ae;</sup>. A single intravenous dose often doubles or triples factor VIII clotting activity. Alternatively, a multi-use nasal formulation of DDAVP<sup>&#x000ae;</sup> Nasal may be more convenient.</p>
          <p>Note: Hemophilia genotype influences DDAVP<sup>&#x000ae;</sup> response [<xref ref-type="bibr" rid="hemo-a.REF.castaman.2009.1824">Castaman et al 2009</xref>, <xref ref-type="bibr" rid="hemo-a.REF.nance.2013.720">Nance et al 2013</xref>].</p>
          <p><bold>Immune tolerance therapy.</bold> Alloimmune inhibitors to factor VIII greatly compromise the ability to manage bleeding episodes [<xref ref-type="bibr" rid="hemo-a.REF.fogarty.2013">Fogarty &#x00026; Kessler 2013</xref>]. High titer inhibitors can often be eliminated by immune tolerance therapy [<xref ref-type="bibr" rid="hemo-a.REF.hay.2012.1335">Hay &#x00026; DiMichele 2012</xref>]. Individuals with large gene deletions are less likely to respond to immune tolerance than individuals with other types of variants [<xref ref-type="bibr" rid="hemo-a.REF.coppola.2009.1809">Coppola et al 2009</xref>].</p>
        </sec>
        <sec id="hemo-a.Prevention_of_Primary_Manifestati">
          <title>Prevention of Primary Manifestations</title>
          <p>Prophylactic treatment is recommended by the National Hemophilia Foundation and the World Federation of Hemophilia for children with severe hemophilia and is usually administered as infusions of factor VIII concentrate three times a week or every other day to maintain factor VIII clotting activity above 1%, although a less intense regimen may provide protection for some affected boys [<xref ref-type="bibr" rid="hemo-a.REF.fischer.2002.753">Fischer et al 2002</xref>, <xref ref-type="bibr" rid="hemo-a.REF.feldman.2006.1228">Feldman et al 2006</xref>]. Newer modified recombinant products with longer half-lives allow less frequent infusions.</p>
          <list list-type="bullet">
            <list-item>
              <p>Factor VIII concentrate infusions given prophylactically in young boys before or just after their first few joint bleeds can nearly eliminate spontaneous bleeding and prevent chronic joint disease [<xref ref-type="bibr" rid="hemo-a.REF.mancojohnson.2007.535">Manco-Johnson et al 2007</xref>].</p>
            </list-item>
            <list-item>
              <p>The greatest benefit is seen in affected individuals who start therapy before age 2.5 to three years. Routine prophylaxis begun later in childhood or in adults significantly decreases bleeding episodes [<xref ref-type="bibr" rid="hemo-a.REF.valentino.2012.359">Valentino et al 2012</xref>, <xref ref-type="bibr" rid="hemo-a.REF.mancojohnson.2013.1119">Manco-Johnson et al 2013</xref>, <xref ref-type="bibr" rid="hemo-a.REF.mondorf.2013.558">Mondorf et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>"Secondary" prophylaxis, started after some joint damage has occurred, can be given on a long-term basis or around periods of increased activity or surgical procedures. An increasing number of adults with hemophilia are on long-term prophylaxis and clinical benefit is being documented in short- and long-term studies.</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemo-a.Prevention_of_Secondary_Complicat">
          <title>Prevention of Secondary Complications</title>
          <p>Reduction of bleeding and chronic joint disease is achieved by prophylactic treatment and prompt effective treatment of bleeding, including by use of home therapy. Many recombinant products are now created without human- or animal-derived proteins in the process or final product. Virucidal treatment of plasma-derived concentrates has eliminated the risk of HIV transmission since 1985, and of hepatitis B and C viruses since 1990.</p>
        </sec>
        <sec id="hemo-a.Surveillance">
          <title>Surveillance</title>
          <p>Persons with hemophilia who are followed at hemophilia treatment centers (HTCs) (see <xref ref-type="sec" rid="hemo-a.Resources">Resources</xref>) have lower mortality than those who are not [<xref ref-type="bibr" rid="hemo-a.REF.soucie.2000.437">Soucie et al 2000</xref>, <xref ref-type="bibr" rid="hemo-a.REF.pai.2016">Pai et al 2016</xref>].</p>
          <p>Young children with severe or moderate hemophilia A should be evaluated at an HTC (accompanied by their parents) every six to 12 months to review their history of bleeding episodes and adjust treatment plans as needed. Early signs and symptoms of possible bleeding episodes are reviewed. The assessment should also include a joint and muscle evaluation, an inhibitor screen, and a discussion of any other problems related to the individual's hemophilia and family and community support.</p>
          <p>Screening for alloimmune inhibitors is indicated at least once during the first ten to 20 treatment days in children with severe hemophilia, and then every three to six months after treatment with factor VIII concentrates has been initiated either for bleeding or prophylaxis. After 50 to 100 exposure days, annual screening and screening prior to elective surgical procedures is sufficient. Testing for inhibitors should be performed in any individual with hemophilia whenever a suboptimal clinical response to treatment is suspected, regardless of disease severity.</p>
          <p>Older children and adults with severe or moderate hemophilia A benefit from at least yearly contact with an HTC (see <xref ref-type="sec" rid="hemo-a.Resources">Resources</xref>) and periodic assessments to review bleeding episodes and treatment plans, evaluate joints and muscles, screen for an inhibitor, perform viral testing if indicated, provide education, and discuss other issues relevant to the individual's hemophilia.</p>
          <p>Individuals with mild hemophilia A can benefit from an assessment at an HTC every one to two years. Affected individuals with comorbidities and other complications or treatment challenges may require more frequent visits.</p>
        </sec>
        <sec id="hemo-a.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Infant males with a family history of hemophilia A should not be circumcised unless hemophilia A is excluded; or, if present, the infant should be treated with factor VIII concentrate directly before and after the procedure.</p>
          <p>Medications and herbal remedies that affect platelet function, including aspirin, should be avoided unless there is strong medical indication, such as in individuals with atherosclerotic cardiovascular disease. Individuals with severe hemophilia usually require clotting factor prophylaxis to allow aspirin and other platelet inhibitory drugs to be used safely [<xref ref-type="bibr" rid="hemo-a.REF.angelini.2016.35">Angelini et al 2016</xref>].</p>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intramuscular injections</p>
            </list-item>
            <list-item>
              <p>Activities that involve a high risk of trauma, particularly of head injury</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemo-a.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p><bold>Identification of at-risk relatives.</bold> A thorough family history may identify other relatives who are at risk but have not been tested (particularly in families with mild hemophilia A).</p>
          <p><bold>Early determination of the genetic status of males at risk.</bold> Either assay of factor VIII clotting activity from a cord blood sample obtained by venipuncture of the umbilical vein (to avoid contamination by amniotic fluid or placenta tissue) or molecular genetic testing for the family-specific <italic toggle="yes">F8</italic> pathogenic variant can establish or exclude the diagnosis of hemophilia A in newborn males at risk. Infants with a family history of hemophilia A should not be circumcised unless hemophilia A is either excluded or, if present, factor VIII concentrate is administered immediately before and after the procedure to prevent delayed oozing and poor wound healing.</p>
          <p>Note: Ideally, the cord blood for factor VIII clotting activity assay should be drawn into a syringe containing one-tenth volume of sodium citrate to avoid clotting and to provide an optimal mixing of the sample with the anticoagulant. If not available a standard blue top tube can be used.</p>
          <p><bold>Determination of genetic status of females at risk.</bold> Approximately 30% of heterozygous females have factor VIII activity lower than 40% and may have abnormal bleeding. In a survey of Dutch heterozygous females, bleeding symptoms correlated with baseline factor clotting activity; there was suggestion of a very mild increase in bleeding even in those with 40% to 60% factor VIII activity [<xref ref-type="bibr" rid="hemo-a.REF.plug.2006.52">Plug et al 2006</xref>]. Therefore, all daughters and mothers of an affected male and other at-risk females should have a baseline factor VIII clotting activity assay to determine if they are at increased risk for bleeding (unless they are known to be non-carriers based on molecular genetic testing). Very occasionally, a female will have particularly low factor VIII clotting activity that may result from heterozygosity for an <italic toggle="yes">F8</italic> pathogenic variant associated with skewed X-chromosome inactivation or, on rare occasion, compound heterozygosity for two <italic toggle="yes">F8</italic> pathogenic variants [<xref ref-type="bibr" rid="hemo-a.REF.pavlova.2009.976">Pavlova et al 2009</xref>].</p>
          <p>It is recommended that the carrier status of a female at risk be established prior to pregnancy or as early in a pregnancy as possible.</p>
          <p>See <xref ref-type="sec" rid="hemo-a.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hemo-a.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p><bold>Obstetric issues.</bold> It is recommended that the carrier status of a female at risk be established prior to pregnancy or as early in a pregnancy as possible.</p>
          <p>If the female is symptomatic (i.e., has baseline factor VIII clotting activity &#x0003c;40%), she will be somewhat protected by the natural rise of factor VIII clotting activity during pregnancy, which may even double by the end of the third trimester. The factor VIII level should be measured in the third trimester to confirm that the level is in the normal range, and if it is not, a plan for factor replacement therapy should be developed. Postpartum factor VIII clotting activity can return to baseline within 48 hours, and postpartum hemorrhage may ensue [<xref ref-type="bibr" rid="hemo-a.REF.lee.2006.301">Lee et al 2006</xref>].</p>
          <p><bold>Newborn males.</bold> Controversy remains as to indications for cesarean section versus vaginal delivery [<xref ref-type="bibr" rid="hemo-a.REF.james.2010.420">James &#x00026; Hoots 2010</xref>, <xref ref-type="bibr" rid="hemo-a.REF.chalmers.2011.208">Chalmers et al 2011</xref>]. In retrospective data analysis of 580 males age 0-2 years with hemophilia, 17 suffered intracranial hemorrhages with delivery, and all but one were delivered vaginally [<xref ref-type="bibr" rid="hemo-a.REF.kulkarni.2009.1281">Kulkarni et al 2009</xref>]. This finding supports the recommendation of cesarean section for hemophilic infants, however, 12 of the 17 were born to women not known to be carriers, suggesting that a planned delivery may mitigate risks. In anticipation of delivery, the relative risks of cesarean section versus vaginal delivery should be considered and discussed with the family and obstetrician in anticipation of delivery so that a coordinated plan can be developed.</p>
        </sec>
        <sec id="hemo-a.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Recombinant factor VIII molecules are being modified to extend their half-life and allow less frequent infusions [<xref ref-type="bibr" rid="hemo-a.REF.young.2016.25">Young &#x00026; Mahlangu 2016</xref>]. Two products are FDA approved, one modified by pegylation and one by Fc fusion; others are in clinical trials. These result in half-life extension by approximately 1.5 fold. Products with greater half-life extension are under development.</p>
          <p>Attempts are being made to learn more about the immunology of inhibitors and ways to prevent them or improve the success rate of immune tolerance [<xref ref-type="bibr" rid="hemo-a.REF.zakarija.2011.636">Zakarija et al 2011</xref>, <xref ref-type="bibr" rid="hemo-a.REF.hay.2012.1335">Hay &#x00026; DiMichele 2012</xref>, <xref ref-type="bibr" rid="hemo-a.REF.astermark.2013.1446">Astermark et al 2013</xref>]. Several novel products that &#x0201c;bypass&#x0201d; the need for factor VIII or factor IX are in clinical or preclinical study [<xref ref-type="bibr" rid="hemo-a.REF.kaufman.2013_1">Kaufman &#x00026; Powell 2013</xref>].</p>
          <p>Clinical trials for gene therapy for hemophilia A have begun and others are in the preclinical phase [<xref ref-type="bibr" rid="hemo-a.REF.spencer.2016.66">Spencer et al 2016</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="hemo-a.Other">
          <title>Other</title>
          <p>Vitamin K does not prevent or control bleeding in hemophilia A.</p>
          <p>Cryoprecipitate is no longer recommended to treat hemophilia A because it is not treated with a virucidal agent.</p>
        </sec>
      </sec>
      <sec id="hemo-a.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hemo-a.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Hemophilia A is inherited in an X-linked manner.</p>
        </sec>
        <sec id="hemo-a.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disorder nor will he be hemizygous for the <italic toggle="yes">F8</italic> pathogenic variant; therefore, he does not require further evaluation/testing.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote (carrier). Note: If a female has more than one affected son and no other affected relatives and the pathogenic variant cannot be detected in her leukocyte DNA, she most likely has germline mosaicism.</p>
            </list-item>
            <list-item>
              <p>If the proband represents a simplex case, the mother of the affected male may or may not be a carrier. (A simplex case refers to an affected male with no family history of hemophilia; ~30% of affected males have no family history of hemophilia A.) Several possibilities regarding his mother's carrier status and the carrier risks of extended family members need to be considered:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The mother is not a carrier and the pathogenic variant occurred <italic toggle="yes">de novo</italic> in the affected male; as many as 15% of probands with a single nucleotide variant and no known family history of hemophilia A have somatic mosaicism for an <italic toggle="yes">F8</italic> pathogenic variant [<xref ref-type="bibr" rid="hemo-a.REF.leuer.2001.75">Leuer et al 2001</xref>].</p>
                </list-item>
                <list-item>
                  <p>The mother is a carrier of a <italic toggle="yes">de novo</italic> pathogenic variant that occurred in one of the following ways:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>As a germline variant (i.e., in the egg or sperm at the time of her conception and thus present in every cell of her body and detectable in her leukocyte DNA). Ninety-eight percent of mothers of a simplex case with an intron 22 inversion are carriers because most of these pathogenic variants occur in spermatogenesis.</p>
                    </list-item>
                    <list-item>
                      <p>As a somatic variant (i.e., a change that occurred very early in embryogenesis, resulting in somatic mosaicism in which the pathogenic variant is present in some but not all cells and may or may not be detectable in her leukocyte DNA)</p>
                    </list-item>
                    <list-item>
                      <p>As germline mosaicism (in which some germ cells have the pathogenic variant and some do not, and in which the pathogenic variant is not detectable in her leukocyte DNA)</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>The mother is a carrier of an inherited pathogenic variant. The mother may have inherited the pathogenic variant either from her mother who has a <italic toggle="yes">de novo</italic> pathogenic variant or from her asymptomatic father who is mosaic for the pathogenic variant. Alternatively, the mother may be a carrier of an inherited pathogenic variant that arose in a previous generation and has been passed on through the family without manifesting symptoms in female carriers.</p>
                  <p>Overall, the mother has an approximately 80% chance of being a carrier when her son is the first affected individual in the family; however, the mother of a severely affected male with an intron 22 inversion has a 98% chance of being a carrier.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Molecular genetic testing combined with linkage analysis can often determine the point of origin of a <italic toggle="yes">de novo</italic> pathogenic variant. Determining the point of origin of a <italic toggle="yes">de novo</italic> pathogenic variant is important for determining which branches of the family are at risk for hemophilia A.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs depends on the mother's genetic status: if the proband's mother is a carrier, each male sib is at a 50% risk of having hemophilia A and each female sib is at a 50% risk of being a carrier.</p>
            </list-item>
            <list-item>
              <p>Germline mosaicism is possible, albeit uncommon. Thus, if an affected male represents a simplex case and if his mother has a normal factor VIII clotting activity and no evidence of her son's <italic toggle="yes">F8</italic> pathogenic variant in DNA from her leukocytes, she is still at an increased (but low) risk of having additional affected children.</p>
            </list-item>
            <list-item>
              <p>All sibs should have factor VIII clotting activity assayed unless molecular genetic testing confirms that they have not inherited the <italic toggle="yes">F8</italic> pathogenic variant present in the family.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>All daughters will be carriers of the <italic toggle="yes">F8</italic> pathogenic variant causing hemophilia A of the same severity as their father's hemophilia.</p>
            </list-item>
            <list-item>
              <p>No sons will inherit the <italic toggle="yes">F8</italic> pathogenic variant, have hemophilia A, or pass it on to their offspring.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The proband's maternal aunts and their offspring may be at risk of being carriers or being affected (depending on their gender, family relationship, and the carrier status of the proband's mother).</p>
        </sec>
        <sec id="hemo-a.Heterozygote_Carrier_Detection">
          <title>Heterozygote (Carrier) Detection</title>
          <p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the pathogenic variant has been identified in the proband.</p>
          <p>Factor VIII clotting activity, or its ratio to von Willebrand factor level, is not a reliable test for determining carrier status: it can only be suggestive if low.</p>
        </sec>
        <sec id="hemo-a.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="hemo-a.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>See <xref ref-type="bibr" rid="hemo-a.REF.ludlam.2005">Ludlam et al [2005]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2005.01070.x/full">full text</ext-link>) for published guidelines for a UK framework for genetic services and <xref ref-type="bibr" rid="hemo-a.REF.thomas.2007.633">Thomas et al [2007]</xref> for findings of a qualitative study in Australia on how cultural and religious issues influence parental attitudes about genetic testing.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being affected or carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hemo-a.Prenatal_Testing_and_Preimplantat">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">F8</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.laurie.2010.783">Laurie et al 2010</xref>] are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="hemo-a.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hemo-a.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="hemo-a.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">F8</italic> spans 186 kb and comprises 26 exons [<xref ref-type="bibr" rid="hemo-a.REF.thompson.2003.11">Thompson 2003</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hemo-a" object-id="hemo-a.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign variants.</bold> Benign variants are seen in the <italic toggle="yes">F8</italic> transcript (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">ExAC database</ext-link>).</p>
          <p><bold>Pathogenic variants.</bold> Gene inversions account for approximately 45% of the <italic toggle="yes">F8</italic> pathogenic variants in severe hemophilia A [<xref ref-type="bibr" rid="hemo-a.REF.kaufman.2013">Kaufman et al 2013</xref>].</p>
          <p><italic toggle="yes">F8</italic> inversions usually occur through recombination between a sequence located within intron 22 and one of two additional copies of homologous sequence that are located 400-500 kb 5&#x02019; from <italic toggle="yes">F8</italic> (about half the distance to the telomere of the long arm of the X chromosome) [<xref ref-type="bibr" rid="hemo-a.REF.bagnall.2006.591">Bagnall et al 2006</xref>]. Of the two most frequent types, cross-over with the distal telomeric sequence (designated as int22h3) is more frequent than with the proximal sequence (designated as int22h2). Infrequently, a third telomeric copy is present and may lead to an alternate intron 22 inversion; alternative patterns can also be seen when the inversion is accompanied by large partial-gene deletions or duplication-insertion events [<xref ref-type="bibr" rid="hemo-a.REF.andrikovics.2003.778">Andrikovics et al 2003</xref>].</p>
          <p>A different recurrent inversion occurs between a 1-kb sequence in intron 1 (designated int1h-1) that is repeated in the reverse orientation (designated int1h-2), approximately 140 kb 5' (telomeric) to <italic toggle="yes">F8</italic> [<xref ref-type="bibr" rid="hemo-a.REF.bagnall.2002.168">Bagnall et al 2002</xref>]; intron 1 inversions occur in up to 3% of families with severe hemophilia A.</p>
          <p>The remaining types of pathogenic variants span the entire spectrum including whole- or partial-gene deletions, large insertions, sequence duplications, small deletions or insertions (usually resulting in frameshifts), splice junction alterations, nonsense variants, and missense variants. These non-inversion variants of <italic toggle="yes">F8</italic> are cataloged (see <related-object source-id="gene" document-id="hemo-a" object-id="hemo-a.molgen.TA">Table A</related-object>, <bold>Locus-Specific Databases</bold>).</p>
          <p><bold>Normal gene product.</bold> Factor VIII is expressed with a 19-amino acid signal peptide; the mature protein has 2332 residues [<xref ref-type="bibr" rid="hemo-a.REF.thompson.2003.11">Thompson 2003</xref>, <xref ref-type="bibr" rid="hemo-a.REF.kaufman.2013">Kaufman et al 2013</xref>]. Its domain structure from the amino terminus is "A1-A2-B-A3-C1-C2" and is homologous to clotting factor V. The three A domains are homologous with ceruloplasmin and the two C domains with discoidins. The known crystal structure of ceruloplasmin has allowed models of the A domains and localization of hemophilic missense variants (see <related-object source-id="gene" document-id="hemo-a" object-id="hemo-a.molgen.TA">Table A</related-object>, <bold>Locus-Specific Databases</bold>). High-resolution crystal structure of a recombinant human C2 domain is known, and hemophilic missense variants have been localized to it and to a model of the homologous C1 domain [<xref ref-type="bibr" rid="hemo-a.REF.liu.2000.979">Liu et al 2000</xref>].</p>
          <p>Factor VIII is synthesized primarily in the liver and circulates as an inactive clotting cofactor that has been variably cleaved towards the carboxy terminus of the B domain prior to secretion. In the circulation, factor VIII is stabilized by binding to von Willebrand factor (VWF). Once activated by trace amounts of thrombin, it is released from VWF and binds to phospholipid membrane surfaces such as those provided by activated platelets. There it interacts with factor IXa to become the "intrinsic system" factor X activator [<xref ref-type="bibr" rid="hemo-a.REF.stoilovamcphie.2002.1215">Stoilova-McPhie et al 2002</xref>]. Intrinsic factor X activation is a critical step in the early stages of coagulation.</p>
          <p><bold>Abnormal gene product.</bold> Abnormal gene products vary from deficiency caused by absence of detectable protein (including the majority of individuals with severe hemophilia A) to those with normal levels of a dysfunctional protein. Pathogenic variants may result in reduced levels of factor VIII clotting activity and antigen caused by impaired secretion of factor VIII or instability of factor VIII in circulation. Certain premature termination codons, gene inversions, or gross gene alterations causing severe hemophilia A have an increased risk of being complicated by inhibitor development [<xref ref-type="bibr" rid="hemo-a.REF.hay.2006.591">Hay et al 2006</xref>, <xref ref-type="bibr" rid="hemo-a.REF.salviato.2007.361">Salviato et al 2007</xref>, <xref ref-type="bibr" rid="hemo-a.REF.coppola.2009.1809">Coppola et al 2009</xref>, <xref ref-type="bibr" rid="hemo-a.REF.gouw.2012.2922">Gouw et al 2012</xref>, <xref ref-type="bibr" rid="hemo-a.REF.astermark.2013.1446">Astermark et al 2013</xref>, <xref ref-type="bibr" rid="hemo-a.REF.eckhardt.2013.1954">Eckhardt et al 2013</xref>].</p>
        </sec>
      </sec>
      <sec id="hemo-a.References">
        <title>References</title>
        <sec id="hemo-a.Published_Guidelines_Regarding_Ge">
          <title>Published Guidelines Regarding Genetic Testing (for the UK)</title>
          <ref-list id="hemo-a.Published_Guidelines_Regarding_Ge.reflist0">
            <ref id="hemo-a.REF.keeney.2010">
              <mixed-citation publication-type="web">Keeney S, Mitchell M, Goodeve A. Practice guidelines for the molecular diagnosis of haemophilia A. UK Haemophilia Centre, Doctors&#x02019; Organisation (UKHCDO), Haemophilia Genetics Laboratory Network, and Clinical Molecular Genetics Society. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acgs.uk.com/media/774613/haemophilia_a_bpg_revision_sept_2011_approved.pdf">online</ext-link>. 2010. Accessed 1-26-17.</mixed-citation>
            </ref>
            <ref id="hemo-a.REF.ludlam.2005">
              <mixed-citation publication-type="web">Ludlam CA, Pasi KJ, Bolton-Maggs P, Collins PW, Cumming AM, Dolan G, Fryer A, Harrington C, Hill FG, Peake IR, Perry DJ, Skirton H, Smith M. A framework for genetic service provision for haemophilia and other inherited bleeding disorders. UK Haemophilia Centre Doctors' Organisation. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2005.01070.x/full">online</ext-link>. 2005. Accessed 6-20-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hemo-a.Treatment_Guidelines">
          <title>Treatment Guidelines</title>
          <ref-list id="hemo-a.Treatment_Guidelines.reflist0">
            <ref id="hemo-a.REF.srivastava.2013">
              <mixed-citation publication-type="web">Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A. Guidelines for the management of hemophilia. World Federation of Hemophilia. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2012.02909.x/epdf">online</ext-link>. 2013. Accessed 6-20-17.</mixed-citation>
            </ref>
            <ref id="hemo-a.REF.pai.2016">
              <mixed-citation publication-type="web">Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, Lane SJ, Makris M, Riker E, Santesso N, Soucie JM, Yeung CHT, Iorio A, Sch&#x000fc;nemann HJ. NHF-McMaster guideline on care models for haemophilia management. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/hae.13008/epdf">online</ext-link>. 2016. Accessed 6-20-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hemo-a.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hemo-a.Literature_Cited.reflist0">
            <ref id="hemo-a.REF.andrikovics.2003.778">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andrikovics</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bors</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marosi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varadi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tordai</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Analysis of large structural changes of the factor VIII gene, involving intron 1 and 22, in severe hemophilia A.</article-title>
                <source>Haematologica</source>
                <volume>88</volume>
                <fpage>778</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">12857556</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.angelini.2016.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Angelini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konkle</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sood</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Aging among persons with hemophilia: contemporary concerns.</article-title>
                <source>Semin Hematol</source>
                <volume>53</volume>
                <fpage>35</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">26805905</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.astermark.2013.1446">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Astermark</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donfield</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomperts</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menius</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessing</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMichele</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkler</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berntorp</surname>
                    <given-names>E</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2013</year>
                <article-title>The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.</article-title>
                <source>Blood</source>
                <volume>121</volume>
                <fpage>1446</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">23223434</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.bagnall.2006.591">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bagnall</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Int22h-related inversions causing hemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection.</article-title>
                <source>J Thromb Haemost</source>
                <volume>4</volume>
                <fpage>591</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16460442</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.bagnall.2002.168">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bagnall</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waseem</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannelli</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A.</article-title>
                <source>Blood</source>
                <volume>99</volume>
                <fpage>168</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">11756167</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.castaman.2009.1824">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giacomelli</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santagostino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A.</article-title>
                <source>J Thromb Haemost</source>
                <volume>7</volume>
                <fpage>1824</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">19719828</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.chalmers.2011.208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chalmers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brennand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liesner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>M</given-names>
                  </name>
                  <collab>Paediatric Working Party of the United Kingdom Haemophilia Doctors&#x02019; Organization</collab>
                </person-group>
                <year>2011</year>
                <article-title>Guideline on the management of haemophilia in the fetus and neonate.</article-title>
                <source>Br J Haematol</source>
                <volume>154</volume>
                <fpage>208</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">21554256</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.coppola.2009.1809">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coppola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margaglione</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santagostino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grandone</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Minno</surname>
                    <given-names>G</given-names>
                  </name>
                  <collab>AICE PROFIT Study Group</collab>
                </person-group>
                <year>2009</year>
                <article-title>Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors.</article-title>
                <source>J Thromb Haemost</source>
                <volume>7</volume>
                <fpage>1809</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">19740093</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.darby.2007.815">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Darby</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kan</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spooner</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giangrande</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludlam</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.</article-title>
                <source>Blood</source>
                <volume>110</volume>
                <fpage>815</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">17446349</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.duga.2013.621">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duga</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomon</surname>
                    <given-names>O.</given-names>
                  </name>
                </person-group>
                <article-title>Congenital factor XI deficiency: an update.</article-title>
                <source>Semin Thromb Hemost.</source>
                <year>2013</year>
                <month>Sep</month>
                <volume>39</volume>
                <fpage>621</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">23929304</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.eckhardt.2013.1954">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eckhardt</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Velzen</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astermark</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brons</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cnossen</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dors</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Escuriola-Ettingshausen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamulyak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Heerde</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermans</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmstr&#x000f6;m</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jimenez-Yuste</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keenan</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klamroth</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laros-van Gorkom</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leebeek</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liesner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e4;kipernaa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Male</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mauser-Bunschoten</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzucconi</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McRae</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meijer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morfini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nijziel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peerlinck</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platokouki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reitter-Pfoertner</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santagostino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schinco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smiers</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siegmund</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagliaferri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yee</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamphuisen</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Bom</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fijnvandraat</surname>
                    <given-names>K</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.</article-title>
                <source>Blood.</source>
                <year>2013</year>
                <volume>122</volume>
                <fpage>1954</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">23926300</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.elmaarri.2005.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>El-Maarri</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herbiniaux</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graw</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terzic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watzka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brackmann</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schramm</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanfland</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwaab</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene.</article-title>
                <source>J Thromb Haemost</source>
                <volume>3</volume>
                <fpage>332</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15670040</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.feldman.2006.1228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feldman</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivard</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Israels</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poon</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demers</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luke</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babyn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLimont</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanchette</surname>
                    <given-names>VS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.</article-title>
                <source>J Thromb Haemost</source>
                <volume>4</volume>
                <fpage>1228</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">16706965</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.fischer.2002.753">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astermark</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Bom</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljung</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berntorp</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grobbee</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>HM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.</article-title>
                <source>Haemophilia</source>
                <volume>8</volume>
                <fpage>753</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">12410643</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.fogarty.2013">
              <mixed-citation publication-type="book">Fogarty PF, Kessler CM. Hemophilia A and B. In: Kitchens CS, Kessler CM, Konkle BA, eds. <italic toggle="yes">Consultative Hemostasis and Thrombosis.</italic> 3 ed. Philadelphia, PA: Elsevier Saunders; 2013:45-59.</mixed-citation>
            </ref>
            <ref id="hemo-a.REF.gouw.2012.2922">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gouw</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astermark</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Groot</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margaglione</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thrompson</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Heerde</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boekhorst</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>le Cessie</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Bom</surname>
                    <given-names>JG</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systemic review and meta-analysis.</article-title>
                <source>Blood</source>
                <volume>119</volume>
                <fpage>2922</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">22282501</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.hay.2006.591">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeling</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liesner</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.</article-title>
                <source>Br J Haematol</source>
                <volume>133</volume>
                <fpage>591</fpage>
                <lpage>605</lpage>
                <pub-id pub-id-type="pmid">16704433</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.hay.2012.1335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMichele</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>The principal results of the International Immune Tolerance Study: a randomized dose comparison.</article-title>
                <source>Blood.</source>
                <year>2012</year>
                <volume>119</volume>
                <fpage>1335</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">22101900</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.hay.2011.6367">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chalmers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liesner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maclean</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rangarajan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>PW</given-names>
                  </name>
                </person-group>
                <article-title>Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>117</volume>
                <fpage>6367</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">21471523</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.james.2010.420">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoots</surname>
                    <given-names>WK</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery.</article-title>
                <source>Haemophilia</source>
                <volume>16</volume>
                <fpage>420</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20028425</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.johnsen.2017.824">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnsen</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huston</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberge</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kircher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Josephson</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shendure</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruuska</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koerper</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierce</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aschman</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konkle</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2017</year>
                <article-title>Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.</article-title>
                <source>Blood Advances</source>
                <volume>1</volume>
                <fpage>824</fpage>
                <lpage>834</lpage>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.josephson.2013">
              <mixed-citation publication-type="other">Josephson N. The hemophilias and their clinical management. Hematology Am Soc Hematol Educ Program. 2013;2013:261-7.</mixed-citation>
            </ref>
            <ref id="hemo-a.REF.kaufman.2013">
              <mixed-citation publication-type="book">Kaufman RJ, Fay PJ, Popolo L, Ortel TL. Factor V and factor VIII. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, eds. <italic toggle="yes">Hemostasis and Thrombosis: Basic Principles and Clinical Practice</italic>. 6 ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2013:179-96</mixed-citation>
            </ref>
            <ref id="hemo-a.REF.kaufman.2013_1">
              <mixed-citation publication-type="other">Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Hematology Am Soc Hematol Educ Program. 2013;2013:30-6.</mixed-citation>
            </ref>
            <ref id="hemo-a.REF.keeney.2011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keeney</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cumming</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donnell</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nash</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: haemophilia A.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2011</year>
                <volume>19</volume>
                <issue>11</issue>
                <pub-id pub-id-type="pmid">21654722</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.kemballcook.1998.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kemball-Cook</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuddenham</surname>
                    <given-names>EGD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wacey</surname>
                    <given-names>AI</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The factor VIII structure and mutation resource site: HAMSTeRS v4.</article-title>
                <source>Nucleic Acids Res</source>
                <volume>26</volume>
                <fpage>216</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9399839</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.kempton.2010.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kempton</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Inhibitors in previously treated patients: a review of the literature.</article-title>
                <source>Haemophilia</source>
                <volume>16</volume>
                <fpage>61</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20536987</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.kulkarni.2009.1281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kulkarni</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lusher</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Presley</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koerper</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathew</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abshire</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dimichele</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoots</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janco</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nugent</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evatt</surname>
                    <given-names>B</given-names>
                  </name>
                  <collab>Haemophilia Treatment Center Network Investigators</collab>
                </person-group>
                <year>2009</year>
                <article-title>Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project.</article-title>
                <source>Haemophilia</source>
                <volume>15</volume>
                <fpage>1281</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">19637999</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.laurie.2010.783">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Laurie</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harraway</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fellowes</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillipson</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benny</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches.</article-title>
                <source>J Thromb Haemost</source>
                <volume>8</volume>
                <fpage>783</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20102489</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.lee.2006.301">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavord</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolton-Maggs</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollard</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinchcliffe-Wood</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadir</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization.</article-title>
                <source>Haemophilia</source>
                <volume>12</volume>
                <fpage>301</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">16834731</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.leuer.2001.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leuer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavergne</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludwig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fregin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eigel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljung</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olek</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Somatic mosaicism in hemophilia A: a fairly common event.</article-title>
                <source>Am J Hum Genet</source>
                <volume>69</volume>
                <fpage>75</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">11410838</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.liu.2000.979">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shen</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakaya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pratt</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujikawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davie</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoddard</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.</article-title>
                <source>Blood</source>
                <volume>96</volume>
                <fpage>979</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">10910913</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.luck.2004.234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Luck</surname>
                    <given-names>JV</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez-Merchan</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghalambor</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zahiri</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finn</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hemophilic arthropathy.</article-title>
                <source>J Am Acad Orthop Surg</source>
                <volume>12</volume>
                <fpage>234</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">15473675</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.ludlam.2005.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ludlam</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolton-Maggs</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cumming</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dolan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fryer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrington</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skirton</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A framework for genetic service provision for haemophilia and other inherited bleeding disorders.</article-title>
                <source>Haemophilia</source>
                <volume>11</volume>
                <fpage>145</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">15810917</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.mancojohnson.2007.535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abshire</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riske</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hacker</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kilcoyne</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingram</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Funk</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoots</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchanan</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMichele</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Recht</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leissinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleak</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathew</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsunaga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medeiros</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nugent</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McRedmond</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evatt</surname>
                    <given-names>BL</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.</article-title>
                <source>N Engl J Med</source>
                <volume>357</volume>
                <fpage>535</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">17687129</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.mancojohnson.2013.1119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kempton</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reding</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lissitchkov</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goranov</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gercheva</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rusen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghinea</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uscatescu</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rescia</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hong</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).</article-title>
                <source>J Thromb Haemost</source>
                <volume>11</volume>
                <fpage>1119</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">23528101</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.miller.2012.375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellingsen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driggers</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Payne</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hooper</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.</article-title>
                <source>Haemophilia</source>
                <volume>18</volume>
                <fpage>375</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">22103590</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.mondorf.2013.558">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mondorf</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalnins</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klamroth</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy.</article-title>
                <source>Haemophilia</source>
                <volume>19</volume>
                <fpage>558</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">23560639</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.nakaya.2001.977">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakaya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Some factor VIII exon 14 frameshift mutations cause moderately severe haemophilia A.</article-title>
                <source>Br J Haematol</source>
                <volume>115</volume>
                <fpage>977</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">11843836</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.nance.2013.720">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nance</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolgiano</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Josephson</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konkle</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Factor VIII mutation and desmopressin-responsiveness in 62 patients with mild hemophilia A.</article-title>
                <source>Haemophilia</source>
                <volume>19</volume>
                <fpage>720</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">23711294</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.pai.2016.6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Key</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curtis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feinstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lane</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riker</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santesso</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeung</surname>
                    <given-names>CHT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iorio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000fc;nemann</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>NHF-McMaster guideline on care models for haemophilia management.</article-title>
                <source>Haemophilia</source>
                <volume>22</volume>
                <supplement>Suppl 3</supplement>
                <fpage>6</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">27348396</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.paroskie.2015.223">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Paroskie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gailani</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeBaun</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidonio</surname>
                    <given-names>RF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>A cross-sectional study of bleeding phenotype in haemophilia A carriers.</article-title>
                <source>Br J Haematol</source>
                <volume>170</volume>
                <fpage>223</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">25832012</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.pavlova.2009.976">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pavlova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brondke</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;sebeck</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollmann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srivastava</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Molecular mechanisms underlying hemophilia A phenotype in seven females.</article-title>
                <source>J Thromb Haemost</source>
                <volume>7</volume>
                <fpage>976</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19302446</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.plug.2006.52">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plug</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mauser-Bunschoten</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brocker-Vriends</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Amstel</surname>
                    <given-names>HK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Bom</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diemen-Homan</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemse</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosendaal</surname>
                    <given-names>FR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Bleeding in carriers of hemophilia.</article-title>
                <source>Blood</source>
                <volume>108</volume>
                <fpage>52</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16551972</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.radic.2009.1183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Radic</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuccoli</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abelleyro</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larripa</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Brasi</surname>
                    <given-names>CD</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Inverse shifting PCR based prenatal diagnosis of hemophilia-causative inversions involving int22h and int1h hotspots from chorionic villus samples.</article-title>
                <source>Prenat Diagn</source>
                <volume>29</volume>
                <fpage>1183</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19842127</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.riccardi.2009.1234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riccardi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivolta</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franchini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pattacini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neri</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagliaferri</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Characterization of a novel mutation in the F8 promoter region associated with mild hemophilia A and resistance to DDAVP therapy.</article-title>
                <source>J Thromb Haemost.</source>
                <year>2009</year>
                <volume>7</volume>
                <fpage>1234</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19422439</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.rossetti.2008.830">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radic</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larripa</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Brasi</surname>
                    <given-names>CD</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Developing a new generation of tests for genotyping hemophilia-causative rearrangements involving int22h and int1h hotspots in the factor VIII gene.</article-title>
                <source>J Thromb Haemost</source>
                <volume>6</volume>
                <fpage>830</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18284600</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.salviato.2007.361">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salviato</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belvini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radossi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sartori</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierobon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanotto</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gandini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagariello</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors.</article-title>
                <source>Haemophilia</source>
                <volume>13</volume>
                <fpage>361</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">17610549</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.schwarz.2013.113">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astermark</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menius</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrington</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donfield</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomperts</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkler</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berntorp</surname>
                    <given-names>E</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.</article-title>
                <source>Haemophilia.</source>
                <year>2013</year>
                <volume>19</volume>
                <fpage>113</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22958194</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.soucie.2000.437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nuss</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evatt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdelhak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolakoski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilber</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.</article-title>
                <source>Blood</source>
                <volume>96</volume>
                <fpage>437</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">10887103</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.spencer.2016.66">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>HT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riley</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doering</surname>
                    <given-names>CB</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>State of the art: gene therapy in haemophilia.</article-title>
                <source>Haemophilia</source>
                <volume>22</volume>
                <supplement>Suppl 5</supplement>
                <fpage>66</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">27405679</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.srivastava.2013.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Srivastava</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewer</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mauser-Bunschoten</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Key</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitchen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Llinas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludlam</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahlangu</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulder</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poon</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Street</surname>
                    <given-names>A</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2013</year>
                <article-title>Guidelines for the management of hemophilia.</article-title>
                <source>Haemophilia</source>
                <volume>19</volume>
                <fpage>e1</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">22776238</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.stoilovamcphie.2002.1215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stoilova-McPhie</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villoutreix</surname>
                    <given-names>BO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mertens</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemball-Cook</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holzenburg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography.</article-title>
                <source>Blood</source>
                <volume>99</volume>
                <fpage>1215</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">11830468</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.stonebraker.2010.20">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stonebraker</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolton-Maggs</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brooker</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A study of variations in the reported haemophilia A prevalence around the world.</article-title>
                <source>Haemophilia.</source>
                <volume>16</volume>
                <fpage>20</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">19845775</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.thomas.2007.633">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herbert</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Street</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnes</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komesaroff</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Attitudes towards and beliefs about genetic testing in the haemophilia community: a qualitative study.</article-title>
                <source>Haemophilia</source>
                <volume>13</volume>
                <fpage>633</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17880455</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.thompson.2003.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Structure and function of the factor VIII gene and protein.</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>29</volume>
                <fpage>11</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">12640560</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.valentino.2012.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mamonov</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hellmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quon</surname>
                    <given-names>DV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chybicka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patrone</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>WY</given-names>
                  </name>
                  <collab>Prophylaxis Study Group</collab>
                </person-group>
                <article-title>A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.</article-title>
                <source>J Thromb Haemost.</source>
                <year>2012</year>
                <volume>10</volume>
                <fpage>359</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">22212248</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.viel.2009.1618">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Viel</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ameri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abshire</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iyer</surname>
                    <given-names>RV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutcher</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Channell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernstrom</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakaya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almasy</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>TE</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Inhibitors of factor VIII in black patients with hemophilia.</article-title>
                <source>N Engl J Med</source>
                <volume>360</volume>
                <fpage>1618</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">19369668</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.young.2016.25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahlangu</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Extended half-life clotting factor concentrates: results from published clinical trials.</article-title>
                <source>Haemophilia.</source>
                <volume>22</volume>
                <supplement>Suppl 5</supplement>
                <fpage>25</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">27405672</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.zakarija.2011.636">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zakarija</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rademaker</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krudysz-Amblo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butenas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mann</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Alloantibodies to factor VIII in haemophilia.</article-title>
                <source>Haemophilia.</source>
                <volume>17</volume>
                <fpage>636</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21299745</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.zhang.2008.5592">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spreafico</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platzer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callaghan</surname>
                    <given-names>MU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avci</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozbek</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahlangu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haw</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaufman</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchant</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuddenham</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seligsohn</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peyvandi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginsburg</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Genotype-phenotype correlation in combined deficiency of factor V and factor VIII.</article-title>
                <source>Blood</source>
                <volume>111</volume>
                <fpage>5592</fpage>
                <lpage>600</lpage>
                <pub-id pub-id-type="pmid">18391077</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hemo-a.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="hemo-a.Suggested_Reading.reflist0">
            <ref id="hemo-a.REF.carcao.2013.3946">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carcao</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljung</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A.</article-title>
                <source>Blood</source>
                <volume>121</volume>
                <fpage>3946</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">23482934</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.goodeve.2008.491">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular genetic testing of hemophilia A.</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>34</volume>
                <fpage>491</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">19085648</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.marijke_van_den_berg.2016.9">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marijke van den Berg</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Preventing bleeds by treatment: new era for haemophilia changing the paradigm.</article-title>
                <source>Haemophilia</source>
                <volume>22</volume>
                <supplement>Suppl 5</supplement>
                <fpage>9</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">27405669</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.peyvandi.2016.187">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Peyvandi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garagiola</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>The past and future of haemophilia: diagnosis, treatments, and its complications.</article-title>
                <source>Lancet</source>
                <volume>388</volume>
                <fpage>187</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">26897598</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.peyvandi.2013.3423">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Peyvandi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunicki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Genetic sequence analysis of inherited bleeding diseases</article-title>
                <source>Blood</source>
                <volume>122</volume>
                <fpage>3423</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">24124085</pub-id>
              </element-citation>
            </ref>
            <ref id="hemo-a.REF.winikoff.2010.s43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winikoff</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hemophilia carrier status and counseling the symptomatic and asymptomatic adolescent.</article-title>
                <source>J Pediatr Adolesc Gynecol.</source>
                <volume>23</volume>
                <fpage>S43</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21108512</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hemo-a.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hemo-a.Author_History">
          <title>Author History</title>
          <p>Cheryl L Brower, RN, MSPH; Bloodworks Northwest (2008-2011) Frank K Fujimura, PhD, FACMG; GMP Genetics, Inc (2000-2003) Haley Huston, BS (2017-present)Maribel J Johnson, RN, MA; Bloodworks Northwest (2000-2008) Neil C Josephson, MD; Bloodworks Northwest (2011-2017)Barbara A Konkle, MD (2011-present)Shelley Nakaya Fletcher, BS (2011-present)Arthur R Thompson, MD, PhD; University of Washington (2000-2014)</p>
        </sec>
        <sec id="hemo-a.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>22 June 2017 (bk) Revision: based on <related-object link-type="booklink" source-id="gene" document-id="hemo-b" document-type="chapter">Hemophilia B</related-object> update</p>
            </list-item>
            <list-item>
              <p>2 February 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 June 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 September 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>25 March 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>17 August 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>8 May 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>21 September 2000 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>April 2000 (art) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
